Progression of visual loss and time between initial assessment and treatment of wet age-related macular degeneration
The DOI matches its Crossref record; 22 of the 22 references it cites were found in a registry or an index.
Abstract
Purpose To determine whether the time elapsed from initial (referral) diagnosis of neovascular (wet) age-related macular degeneration (AMD) to assessment and treatment by a retinal specialist is associated with visual deterioration in the intervening period. Methods A prospective pilot study of 38 consecutive AMD patients who presented with newly diagnosed subfoveal choroidal neovascularization was conducted in a tertiary care retinal practice. All eligible subjects underwent clinical examination and digital fluorescein angiography at the time of assessment by a retinal specialist. Correlations were performed to assess the association between continuous independent variables and any visual deterioration since initial diagnosis. Multivariate linear regression models with stepwise techniques were used to evaluate any association between visual progression and time elapsed, while controlling for potential clinical covariates. Results Of the 38 patients, 32 (84%) met the inclusion and exclusion criteria; no differences in important variables were noted between those included and those excluded. The median time between initial diagnosis and referral assessment and treatment was 28 days (interquartile range=36.5 days); some degree of visual loss developed in 14 (44%) of the subjects. The elapsed time was correlated with progression of visual loss (r=0.50, p=0.003). Multivariate linear regression demonstrated that only time elapsed and lesion type based on fluorescein angiography we…
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“Similar delay in access to services has been recorded in Canada, 67 Spain 68 and Germany.69,70”
From Defining response to anti-VEGF therapies in neovascular AMD (2015) · cites this paper as [67]
Citations
Cites
Pegaptanib for neovascular age-related macular degeneration
Gragoudas, E. S., Adamis, A. P., Cunningham, E. T., Feinsod, M., & Guyer, D. R. (2004) · New England Journal of Medicine · doi:10.1056/nejmoa042760 · Cited by 2,337
(1999) · Archives of Ophthalmology · doi:10.1001/archopht.117.10.1329 · Cited by 2,192
Risk factors for age-related macular degeneration
Smith, W., Assink, J., Klein, R., Mitchell, P., Klaver, C. C. W., Klein, B. E. K., Hofman, A., Jensen, S., Wang, J. J., & de Jong, P. T. V. M. (2001) · Ophthalmology · doi:10.1016/s0161-6420(00)00580-7 · Cited by 1,071
(1991) · Archives of Ophthalmology · doi:10.1001/archopht.1991.01080090044025 · Cited by 495
Gragoudas, E. S., Adamis, A. P., Cunningham, E. T., Feinsod, M., & Guyer, D. R. (2004) · Cited by 474
Utility Values and Age-related Macular Degeneration
Brown, G. C. (2000) · Archives of Ophthalmology · doi:10.1001/archopht.118.1.47 · Cited by 263
(1994) · Archives of Ophthalmology · doi:10.1001/archopht.1994.01090160076025 · Cited by 234
Clemons, T. E. (2003) · Archives of Ophthalmology · doi:10.1001/archopht.121.2.211 · Cited by 190
(2002) · Archives of Ophthalmology · doi:10.1001/archopht.120.11.1443 · Cited by 178
(2003) · Ophthalmology · doi:10.1016/j.ophtha.2003.08.020 · Cited by 177
Research works printed but not linked: 1
- 2004, NCQA adds four new measures to HEDIS 2005, Qual Lett Healthc Lead, 16, 12
Cited by
The Natural History and Prognosis of Neovascular Age-Related Macular Degeneration
Wong, T., Chakravarthy, U., Klein, R., Mitchell, P., Zlateva, G., Buggage, R., Fahrbach, K., Probst, C., & Sledge, I. (2008) · Ophthalmology · doi:10.1016/j.ophtha.2007.03.008 · Cited by 601
Defining response to anti-VEGF therapies in neovascular AMD
Amoaku, W. M., Chakravarthy, U., Gale, R., Gavin, M., Ghanchi, F., Gibson, J., Harding, S., Johnston, R. L., Kelly, S., Lotery, A., et al. (2015) · Eye · doi:10.1038/eye.2015.48 · Cited by 355
Epidemiology of Major Eye Diseases Leading to Blindness in Europe: A Literature Review
Prokofyeva, E., & Zrenner, E. (2012) · Ophthalmic Research · doi:10.1159/000329603 · Cited by 212
Schmidt-Erfurth, U., Bogunovic, H., Sadeghipour, A., Schlegl, T., Langs, G., Gerendas, B. S., Osborne, A., & Waldstein, S. M. (2018) · Ophthalmology Retina · doi:10.1016/j.oret.2017.03.015 · Cited by 199
Motozawa, N., An, G., Takagi, S. T., Kitahata, S., Mandai, M., Hirami, Y., Yokota, H., Akïba, M., Tsujikawa, A., Takahashi, M., et al. (2019) · Ophthalmology and Therapy · doi:10.1007/s40123-019-00207-y · Cited by 137
Metadata
- Authors
- Oliver-Fernandez, A., Bakal, J., Segal, S., Shah, G. K., Dugar, A., & Sharma, S.
- Affiliations
- Queen's University (CA)
- Washington University in St. Louis (US)
- Pfizer (United States) (US)
- Corresponding author
- Sharma, Sanjay
- Venue
- Canadian Journal of Ophthalmology
- Publisher
- Elsevier BV
- Published
- 2005-06
- Volume
- 40
- Issue
- 3
- Pages
- 313-319
- ISSN
- 0008-4182 (ISSN-L)
- OpenAlex
- W1989515430
- Cited by
- 50
- References
- 22
- Citations by year
- 2026: 1 · 2025: 3 · 2024: 2 · 2023: 3 · 2022: 1 · 2021: 2 · 2020: 3 · 2019: 3 · 2018: 1 · 2017: 3 · 2016: 4 · 2015: 4 · 2014: 3 · 2013: 3 · 2012: 2
- FWCI
- 1.22
- Type
- journal article
- Language
- en
- Open access
- closed
- Licence
- www.elsevier.com/tdm/userlicense/1.0/ (tdm)
- www.elsevier.com/legal/tdmrep-license (tdm)
- Locations
- Canadian Journal of Ophthalmology (publishedVersion)
- PubMed (publishedVersion)
- Topics
- Health Sciences › Medicine › Ophthalmology › Retinal Diseases and Treatments
- Health Sciences › Medicine › Radiology, Nuclear Medicine and Imaging › Retinal Imaging and Analysis
- Health Sciences › Medicine › Ophthalmology › Ocular Diseases and Behçet’s Syndrome
- Keywords
- neovascular age-related macular degeneration, choroidal neovascularization, treatment delay, time to treatment, fluorescein angiography, lesion type, subfoveal neovascularization
- MeSH terms
- Aged, Aged, 80 and over, Female, Fluorescein Angiography, Follow-Up Studies, Fundus Oculi, Humans, Macular Degeneration, Male, Pilot Projects, Prognosis, Prospective Studies, Risk Factors, Time Factors, Vision Disorders, Disease Progression, Choroidal Neovascularization
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Progression of visual loss and time between initial assessment and treatment of wet age-related macular degeneration. https://app.cochat.ai/papers/10.1016/s0008-4182(05)80074-2
- The paper
- Oliver-Fernandez, A., Bakal, J., Segal, S., Shah, G. K., Dugar, A., & Sharma, S. (2005). Progression of visual loss and time between initial assessment and treatment of wet age-related macular degeneration. Canadian Journal of Ophthalmology. https://doi.org/10.1016/s0008-4182(05)80074-2
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.